Patents by Inventor John A. Kellum, Jr.
John A. Kellum, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11693014Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: January 15, 2020Date of Patent: July 4, 2023Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Kai Singbartl, John A. Kellum, Jr.
-
Patent number: 11243202Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.Type: GrantFiled: April 8, 2016Date of Patent: February 8, 2022Assignees: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTERInventors: Paul McPherson, John A. Kellum, Jr., Alexander Zarbock
-
Publication number: 20200150132Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: January 15, 2020Publication date: May 14, 2020Inventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 10557856Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: GrantFiled: September 16, 2011Date of Patent: February 11, 2020Assignee: University Of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Publication number: 20180074054Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.Type: ApplicationFiled: April 8, 2016Publication date: March 15, 2018Applicants: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS TEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTERInventors: Paul McPherson, John A. Kellum, Jr., Alexander Zarbock
-
Patent number: 9551720Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.Type: GrantFiled: January 20, 2012Date of Patent: January 24, 2017Assignee: University of Pittsburgh—Of the Commonwaelth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Publication number: 20150241415Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect hyaluronic acid as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.Type: ApplicationFiled: August 9, 2013Publication date: August 27, 2015Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf, Kai Singbartl, John A. Kellum, JR.
-
Patent number: 8827943Abstract: In one aspect, the invention provides a device comprising a catheter. In another aspect, the invention provides a method of removing an agent from blood.Type: GrantFiled: March 14, 2013Date of Patent: September 9, 2014Assignee: University of Pittsburg—Of The Commonwealth System of Higher EducationInventors: George Oliviu Angheloiu, John A. Kellum, Jr., William D. Anderson, Catalin Toma
-
Publication number: 20130323751Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.Type: ApplicationFiled: January 20, 2012Publication date: December 5, 2013Applicant: University of Pittsburgh - of the Common-Wealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, JR.
-
Patent number: 8501489Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: GrantFiled: September 23, 2009Date of Patent: August 6, 2013Assignee: University of Pittsburgh—Of The Commonwealth System of Higher EducationInventors: Kai Singbartl, John A. Kellum, Jr.
-
Patent number: 8398576Abstract: The invention provides a system and a method for removal of contrast from blood. In one aspect, the invention provides a catheter for removal of contrast from the veins that drain the cerebral circulation. In a second aspect, the invention provides a method for removing contrast from blood by contacting the blood with a sorbent.Type: GrantFiled: April 2, 2008Date of Patent: March 19, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: George Oliviu Angheloiu, John A. Kellum, Jr., William D. Anderson, Catalin Toma
-
Publication number: 20120077690Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and/or transforming growth factor ?1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.Type: ApplicationFiled: September 16, 2011Publication date: March 29, 2012Inventors: Kai Singbartl, John A. Kellum, JR.
-
Publication number: 20100081148Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of hyaluronic acid can be used to determine whether a patient having suffered acute kidney injury will require long-term dialysis.Type: ApplicationFiled: September 23, 2009Publication date: April 1, 2010Inventors: Kai Singbartl, John A. Kellum, JR.
-
Publication number: 20080281248Abstract: The invention provides a system and a method for removal of contrast from blood. In one aspect, the invention provides a catheter for removal of contrast from the veins that drain the cerebral circulation. In a second aspect, the invention provides a method for removing contrast from blood by contacting the blood with a sorbent.Type: ApplicationFiled: April 2, 2008Publication date: November 13, 2008Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: George Oliviu Angheloiu, John A. Kellum, JR., William D. Anderson, Catalin Toma